Dr. Reddy's Laboratories announces the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") has announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz® (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

The Akovaz® brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

Dr. Reddy's Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4800.55 as compared to the previous close of Rs. 4670.05. The total number of shares traded during the day was 29306 in over 4507 trades.

The stock hit an intraday high of Rs. 4835.00 and intraday low of 4630.20. The net turnover during the day was Rs. 139685056.00.

Source : Equity Bulls

Keywords

DrReddysLaboratoriesLimited INE089A01023 ProductLaunch USMarket